The WT2725 dosing emulsion was administered as a monotherapy to patients with advanced malignancies (glioblastoma, AML, NSCLC, and ovarian cancer) known to overexpress the WT1 protein in the majority of patients3,4,41. The gene discussed is WT1; the disease is acute myeloid leukemia.